Thursday, September 27, 2018 8:31:12 AM
Madrigal Pharmaceuticals Inc (MDGL)
Jarred lighting could be the only way to describe biotech stock Madrigal Pharmaceuticals (NASDAQ:MDGL). After two successful initial trials for its MGL-3196 drug, shares of MGDL have been off to the races — jumping over 128% since the beginning of the year. And that jump is pretty justified.
That key drug is a hormone inhibitor that is absorbed in the liver and early trials it performed beautifully. Patients receiving MGL-3196 exhibited a highly significant reduction in liver fat versus those on placebo. But what was really was impressive is that roughly 50% of the patients also saw their liver fibrosis resolved. That’s massive because fibrosis resolution would be considered an FDA-approvable endpoint for a study. It one quick shot, MDGL went from an unknown to one of the biggest NASH players. The biotech is currently planning a late-stage study for MGL-3196 soon.
But retail investors aren’t the only ones looking at MDGL in spades. It’s starting to get attention from other suitors as well. Rumors have begun to swirl that Bristol-Myers Squibb (NYSE:BMY) is looking into buying the firm. Management seems pretty receptive to the buyout as well.
The only problem is that Madrigal’s pipeline is literally just this drug. Investors have already placed a lot of faith into it and a buyout. If those don’t happen, MDGL will come crashing back to earth ASAP. On the flipside, the gains could be endless if it manages to get the dug to market. When it comes to the biotech stocks on this list, it has the highest risk/reward.
https://finance.yahoo.com/news/5-biotech-stocks-play-sector-192123669.html
Recent MDGL News
- Madrigal Statement on the Passing of Dr. Stephen Harrison • GlobeNewswire Inc. • 04/24/2024 08:00:00 PM
- Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/16/2024 08:05:00 PM
- Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/03/2024 08:05:00 PM
- Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering • GlobeNewswire Inc. • 03/19/2024 03:58:56 AM
- Madrigal Pharmaceuticals Announces Proposed Public Offering • GlobeNewswire Inc. • 03/18/2024 08:04:05 PM
- Adobe Stock Drops Following Below-Estimate Projections, Cardlytics Surges with Unexpected Profit, and More News • IH Market News • 03/15/2024 11:30:55 AM
- Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis • GlobeNewswire Inc. • 03/14/2024 08:15:00 PM
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/06/2024 09:05:00 PM
- Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:01:31 PM
- Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer • GlobeNewswire Inc. • 02/28/2024 12:01:00 PM
- Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/28/2024 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 11:32:35 AM
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/21/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:50:08 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 02:21:37 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 10:55:57 PM
- Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine • GlobeNewswire Inc. • 02/08/2024 01:00:00 PM
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/06/2024 09:05:00 PM
- Madrigal Pharmaceuticals Announces Additions to Its Leadership Team • GlobeNewswire Inc. • 01/29/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 11:04:23 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM